Most importantly, a homolog of DGAT2, DGAT1, has been extensively pursued as a therapeutic target for obesity and diabetes yet with limited clinical success (see below), and we wanted to explore if DGAT2 would be a more viable target. This evidence concerns the gene DGAT2 and obesity due to melanocortin 4 receptor deficiency.